FHC #214: Revisiting GLP-1 prices and ChatGPT’s early leap forward
About this episode
The episode revisits a conversation on the rapid advancement of technology in healthcare and the persistent high costs of GLP-1 medications.
For the next two weeks, Fixing Healthcare hosts Jeremy Corr and Dr. Robert Pearl will be replaying past episodes of Diving Deep while Dr. Pearl travels and keynotes events around the world. But these aren’t random reruns. They were selected for a reason: to highlight just how quickly technology is advancing and how slowly healthcare is adapting. This week’s flashback revisits a July 2024 conversation recorded shortly after OpenAI released GPT-4o , a major leap forward in generative AI at the time. Less than two years later, the pace of change is striking. Capabilities that once felt groundbreaking now seem primitive compared to what today’s AI tools can accomplish for patients, physicians and healthcare organizations. At the same time, the episode’s broader themes remain remarkably current. Dr. Pearl and Jeremy discuss the future role of generative AI in medicine, how these tools could improve diagnosis and patient monitoring and why healthcare institutions often struggle to embrace transformative technology quickly. The episode also examines another issue that remains unresolved today: the high cost of GLP-1 medications like Wegovy and Ozempic. Dr. Pearl explains why these…
More episodes of Fixing Healthcare Podcast
- FHC #217: GenAI, physician fulfillment & the future of medical practice
- MTT #107: How politics is weakening America’s public health defenses
- FHC #216: An unfiltered look at what legacy means in medicine
- FHC #215: Revisiting healthcare leadership, technology & capitation
Explore listener stats, chart rankings, contacts and more on the Fixing Healthcare Podcast podcast page.